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1. Introduction 
Bone is a dynamic organ that is constantly being broken down and replenished in a process 
known as bone remodeling. Bone remodelling is carried out by two cell types on the bone 
surface; osteoclasts which remove bone via resorption and osteoblasts that subsequently replace 
bone by forming a new bone matrix [1]. Bone remodelling is influenced by many cell types within 
the bone marrow, most obviously including mature osteoblasts and osteoclasts, but also other 
cell types including matrix-embedded osteocytes, osteoblast progenitors, osteoclast precursors, 
macrophages, T lymphocytes [1, 2] and B lymphocytes [3]. A large focus in bone biology is the 
coupling of osteoblasts and osteoclasts in regulating bone formation. However, osteoblasts have 
also been shown to be key regulators of other hematopoietic cells. Of interest in this review is 
the contribution of osteoblasts to the regulation of B lymphopoiesis in mice. 
2. B lymphopoiesis 
B lymphocytes, commonly called B cells, are antibody-producing white blood cells that primarily 
function as a part of the adaptive immune system. B lymphopoiesis is the process of mature B 
lymphocyte formation, which in sequential stages take part in the bone marrow and spleen in 
adult mice. The tightly regulated process of B lymphopoiesis is reliant on intrinsic and extrinsic 
stimuli, the latter predominantly being produced by non-hematopoietic microenvironmental 
cells. 
 
There are two distinct types of B cells that have different origins in the immune system. The most 
primitive B cells (B-1 cells) primarily originate from fetal liver and are sustained through self-
renewal in the periphery [4]. In comparison, conventional B-2 cells (the focus of this review) 
mature in the bone marrow and rely greatly on the bone marrow (BM) microenvironment [5-8].  
 
Conventional B lymphopoiesis of B-2 cells begins in the bone marrow in the medullary cavity of 
bones from hematopoietic stem cells (HSCs). HSCs are rare, multipotent cells that self-renew to 
produce more HSCs and have the capacity to differentiate to form all mature blood cells [9]. The 
fate of HSCs is regulated by cell intrinsic mechanisms (e.g. transcription factors and cell cycle 
regulators) and additionally influenced by extrinsic factors (e.g. cytokines, growth factors, cell-
cell interactions and extracellular matrix components) produced in their microenvironments. 
With respect to lymphopoiesis, HSCs differentiate into common lymphoid progenitors capable of 
forming T and B lymphocyte lineages that develop in the thymus and bone marrow and spleen, 
respectively. B lymphopoiesis occurs through distinct stages of differentiation: in the bone 
marrow, common lymphoid progenitors (CLPs) commit to B-cell-biased lymphoid progenitors 
(BLPs), that form early B lymphocyte precursors known as pre-pro-B lymphocytes, followed by 
pro-B lymphocytes, pre-B lymphocytes and then immature B lymphocytes, these then migrate 
from the bone marrow and mature in the spleen [5]. End-stage B lymphocytes known as plasma 
cells can return to the bone marrow [5] (Figure 1). In the bone marrow, early B lymphopoiesis is 
reliant on factors expressed by non-hematopoietic cells, with different cell types orchestrating 
progression through each stage of early B lymphopoiesis and the homing of terminally 
differentiated plasma cells back to the bone marrow. 
 
The first specified B lymphocyte progenitor is the BLP, which are Ly6D+ CLPs that express lower 
levels of c-kit compared to the CLPs that generate all lymphoid progenitors (ALPs) [10]. The 
transcription factor E2A has been shown to be essential to the generation of BLPs (and 
subsequently all B lymphocytes) from ALPs [10]. The expression of B220 identifies pre-pro-B cells 
that arise from BLPs [11, 12] (Figure 1). Progression to the pro-B lymphocyte stage is induced by 
expression of the transcription factor paired box protein 5 (PAX5) which causes irreversible 
commitment to the B cell lineage and expression of CD19 [12, 13]. As committed B cells develop, 
variable (V), diverse (D) and joining (J) gene segments of the immunoglobin (Ig) heavy and light 
chain loci are shuffled and mutated to create functional B cell antigen receptors (BCRs) and 
enhance antibody diversity [14]. The first Ig loci recombination occurs at the pro-B cell stage 
where expression of recombination-activating genes (RAG1 and RAG2) initiates Ig heavy chain 
rearrangement [14]. In large pre-B lymphocytes the recombined Ig heavy chain pairs with a 
surrogate light chain to form the pre-B cell antigen receptor (pre-BCR) which is then trafficked to 
the cell surface [15]. Antigen-independent signaling through the pre-BCR is crucial for further 
development, stimulating downregulation of RAG1/2, inducing a proliferative burst allowing 
clonal expansion of large pre-B cells [14]. Progression to the small pre-B cell stage is marked by 
downregulation of the surrogate light chain, and upregulation of RAG1/2 to commence light-
chain rearrangement. Assembly and expression of the recombined Ig light chain leads to pairing 
with the rearranged heavy chain and transport to the cell surface of immature B cells, forming 
the BCR complex with CD79a  ?/Őɲ ?ĂŶĚ ? ? ?/Őɴ ?. Immature B cells then go through central 
tolerance to ensure they are non-autoreactive [14]. Immature B cells with autoreactive BCRs can 
be negatively selected and die by neglect or undergo receptor editing. Positive selection occurs 
for immature B cells with unliganded BCRs by phosphoinositide 3-kinase (PI3K) signaling, allowing 
progression to a transitional B cell. Transitional B cells then migrate to the spleen but are sensitive 
to antigen-induced apoptosis during this phase [16]. 
 
 
Figure 1: Simplified schematic of B lymphopoiesis 
Hematopoiesis arises in the bone marrow from hematopoietic stem cells (HSCs). In the lymphoid 
lineage, HSCs give rise to common lymphoid progenitors (CLPs) which form T lymphocytes, B 
lymphocytes and natural killer cells. B lymphocytes continue developing in the bone marrow 
through pre-pro-B, pro-B and pre-B lymphocyte stages, immature B lymphocytes then exit the 
bone marrow and mature in the spleen. End stage plasma cells then return to the bone marrow. 
 
3. Microenvironment regulation of hematopoiesis 
Over the recent decades there has been increasing interest in the role of cells within 
hematopoietic microenvironments (also known as niches) in nurturing healthy [17-19] and 
malignant [20-22]  hematopoiesis and bone remodelling [1, 2] ? ‘DŝĐƌŽĞŶǀŝƌŽŶŵĞŶƚƐ ?Žƌ ‘ŶŝĐŚĞƐ ?
are compartments that function to regulate the numbers and types of hematopoietic cells that 
are developing in the microenvironment by influencing their development into distinct 
hematopoietic cell lineages. Disruption to the function of microenvironment cells can have dire 
consequences for hematopoiesis and bone remodeling and, in turn, can cause serious health 
implications. 
 
Hematopoietic niches are intricate and unique, operating to integrate the complicated processes 
involved in differentiated blood cell production to meet the organisms ? needs. Different niches 
located throughout the bone marrow are responsible for regulating different stages of 
hematopoiesis. Exactly how these distinct niches are organised still requires further investigation, 
although numerous cell types known to play important roles have been identified. These include 
(but are not restricted to); hematopoietic cells (e.g. HSCs, B lymphocytes, T lymphocytes, 
dendritic cells, macrophages, megakaryocytes ), mesenchymal stromal and perivascular cells (e.g. 
Prrx1+ limb bud-derived mesenchymal cells [23], nestin-expressing perivascular cells [24, 25] 
leptin receptor (LepR)-expressing mesenchymal stromal cells [26, 27]), osterix (Osx)-derived 
osteoblast progenitor cells and osteoblasts [23, 28, 29], CXC-motif chemokine ligand 12 (CXCL12) 
abundant reticular (CAR) cells [30, 31] and endothelial cells [26, 27]) (Table 1).  
 
3.1. Transgenic mouse models as a tool for understanding the bone marrow 
microenvironment 
The use of transgenic mice with specific promoter driven Cre-recombinase expression, targeting 
specific microenvironmental cells (Table 1) has greatly enhanced our understanding of the impact 
of these different cell types on distinct hematopoietic cell types. Such studies have utilized cell-
specific deletion of genes such as Cxcl12 and Scf to uncover which cell types are important in 
regulating hematopoiesis via these microenvironmental factors. While transgenic models are 
very useful, it is always important to consider their limitations. For instance, Prrx1-Cre targets 
limb-bud derived mesenchymal cells, hence it will target cells expressing Prrx1 but also any cells 
that are derived from Prrx1-expressing cells, including osteoblasts, chondrocytes and adipocytes. 
Thus phenotypes could result due to alterations to the original cell targeted or any progeny of 
that cell, which could include alterations to numerous cell lineages when primitive cell types are 
targeted. In addition, Prxx1-Cre targets primitive cells in the limb bud mesenchyme, craniofacial 
mesenchyme and flank mesoderm [32]. Hence mesenchymal cells in the limbs, some calvarial 
bones and the sternum will be targeted, but not the vertebrae and thus any local effects will not 
be apparent in the spine. Many of the Cre transgenic mice are also not entirely specific to the cell 
lineage they are often used to study. For example, Dmp1-Cre is used to target late osteoblasts 
and osteocytes but also targets skeletal muscle fibres, some cells in the brain and mesenchymal 
cells in the intestine and stomach [33]. While this may not have a direct impact on the bone 
microenvironment, changes to skeletal muscle could easily influence mechanical loading and 
thus have indirect effects on the bone, being a mechano-sensitive organ. ColϮɲ1-Cre is used to 
study chondrogenic lineage cells but it has also been shown to target some osteoblastic cells. 
Seven day old ŽůϮɲϭ-Cre:Rosa26LacZ mice exhibited LacZ expression in synovial fibroblasts [34] 
and at embryonic day 16.5 LacZ was detected in the periosteum and primary spongiosa in the 
appendicular and axial skeleton [35] ?dŚƵƐ ?ĚĞƐƉŝƚĞƚŚĞĨĂĐƚƚŚĂƚŶĞŝƚŚĞƌƚŚĞŽů ?ɲ ?ŐĞŶĞ [34] nor 
Žů ?ɲ ?-Cre [35] are expressed in osteoblasts, these osteoblastic cells can arise from a cell that 
ŽŶĐĞĞǆƉƌĞƐƐĞĚŽů ?ɲ ?-Cre.  
 
Table 1. Transgenic Cre-recombinase mouse strains used to target mesenchymal cells in the bone 
marrow microenvironment cells 
Cre 
Cell type targeted in bone marrow 
microenvironment 
Other targets outside the bone 
marrow 
Ref 
Prrx1 
Limb bud-derived mesenchymal 
cells  
None reported, but note that the 
vertebrae are not targeted by Prrx1 
[32] 
Nestin 
Neural crest-derived perivascular 
mesenchymal cells  
Yes, strain-dependent, reviewed in 
[17] 
[36-
38] 
LepR 
Perivascular mesenchymal stromal 
cells  
Some brain cells, some 
hematopoietic cells 
[39-
41] 
Gremlin1 
Osteochondroreticular (OCR) stem 
cells 
Intestinal reticular stem cells 
[42] 
Mx1 
Osteolineage-restricted 
stem/progenitor cells and HSCs 
Heart, kidney, liver 
[43, 
44] 
Osx 
Osteoprogenitors, CAR cells, 
hypertrophic chondrocytes, 
adipocytes 
Olfactory glomerular cells, some 
gastric and intestinal epithelial cells 
[45-
47] 
Žůϭɲ1 2.3kb 
(Mouse) 
Osteoblasts 
None reported (the two different 
rat-derived Col2.3 strains have 
other cell targets, reviewed in [17]) 
[48] 
ŽůϮɲϭ 
Chondrocytes, synovial fibroblasts, 
periosteum and primary spongiosa 
in the appendicular and axial 
skeleton 
None reported 
[34, 
35] 
Tagln 
Osteoblasts, majority of CAR cells 
and vinous sinusoidal and 
arteriolar pericytes 
Smooth muscle cells 
[49, 
50] 
Osteocalcin 
Mature osteoblasts, most CAR cells 
and arteriolar pericytes 
 
[51] 
Dmp1 
(9.6kb)* 
Late osteoblasts and osteocytes, 
subset of CAR cells 
Skeletal muscle, brain, intestine, 
stomach 
[33, 
49, 
52] 
*The 8kb Dmp1-Cre strain also targets some brain cells, reviewed in [17]. 
 
 
3.2. Cellular localisation of B lymphocyte niches 
The microenvironment in the bone marrow is known to be essential for commitment to B 
lymphopoiesis and the sequential stages of early B lymphopoiesis. From HSC to immature B 
lymphocytes ready to exit the bone marrow, each stage is regulated by unique supportive niches. 
How these niches are organised for the distinct stages of B lymphocyte development have not 
yet been completely defined. We focus here on the regulation of B lymphopoiesis from the CLP 
stage onwards. 
 
CLPs have been shown to lose the potential to generate all lymphoid cell types when they express 
Ly6D and become BLPs, producing almost exclusively B cells [10]. After commitment to the B 
lymphocyte lineage, early B lymphocyte progenitors progress through distinct niches in the bone 
marrow. Studies using Cxcl12:GFP [53] knock-in mice have shown that pre-pro-B lymphocytes 
localise near CXCL12-abundant reticular (CAR) cells. These cells differentiate into pro-B 
lymphocytes and together with Pre-B I cells [54, 55], localise near Interleukin 7 (IL-7)-secreting 
cells [54, 55]. The IL-7-producing cells have been described as being spindle-shaped reticular cells 
that usually reside in close contact with vessels and express VCAM- ?  ? ? ? ? ? ?W'&Zɲ ? ? ?
(ICAM-1), and BP-1 but not CD31 [54], suggesting these cells are of the mesenchymal lineage. 
While the nature of these reticular cells have not yet been determined, it is possible that they 
are Osx-Cre-targeted osteoblast progenitor cells, which have been shown to express IL-7 [56].  
 
Pre-B II lymphocytes then migrate away from IL-7-expressing cells [54, 55] to stromal cells that 
are scattered throughout the bone marrow. Studies in which pre-B II cells were injected into 
hydroxyurea-treated mice suggest that the pre-B II cells home to cells that are located 
throughout the bone marrow and express Galectin-1 (GAL1) [54]. Immature B lymphocytes 
localise near endothelial cells lining blood vessels [57] prior to these cells exiting the bone 
marrow into the circulation. Some immature B lymphocytes are retained in the bone marrow 
through cannabinoid receptor 2-mediated adhesion to endothelial cells lining sinusoidal vessels 
[57]. 
 
The migration of the developing B lymphocytes through the bone marrow to the distinct B 
lymphocyte niches relies on the expression of different chemokines (such as CXCL12) and 
adhesion molecules, which are required during different stages of B cell development and are 
discussed further below. A deregulation of these factors and other B lymphocyte regulatory 
factors, including cytokines, that are expressed by distinct B lymphocyte niche cells may result in 
changes in BM B lymphopoiesis. Such alterations may include either retention at the niche, or 
extrinsically-mediated alterations to genes that are required for B cell development. There are 
numerous excellent reviews focusing on the intrinsic regulators of B cell development, in 
particular the role of transcription factors that are essential for B lymphopoiesis [12, 58, 59]. Here 
we focus on known extrinsic regulators of B lymphopoiesis, with a particular focus on the roles 
of mesenchymal-derived cells in these processes.  
 
 Figure 2: The bone marrow is the site of early B lymphopoiesis 
Early B lymphopoiesis occurs in the bone marrow. Haematopoietic stem cells (HSCs) differentiate 
to common lymphoid progenitors (CLPs) and then become the earliest committed B cell 
precursor, the pre-pro-B cell. Pre-pro B cells localise next to CXCL12-abundant reticular (CAR) 
cells, then as they differentiate into pro-B cells they localise adjacent to IL-7-expressing stromal 
cells. Pre-B cells localise near Galectin-1-expressing cells within the bone marrow. Immature B 
cells migrate from the bone marrow to mature at the spleen, although some are retained through 
interactions with endothelial cells. End stage plasma cells then return to the bone marrow. 
Osteoblasts are known to play essential roles in regulating B lymphopoiesis. B lymphocytes can 
in turn regulate bone by altering osteoclastogenesis via production of RANKL, which binds to 
RANK on the surface of osteoclast precursors. Mature B lymphocytes have also been shown to 
be a major source of OPG, thereby inhibiting osteoclastogenesis. 
4. The mesenchymal niches for B lymphopoiesis 
Mesenchymal cells, including osteoblast lineage cells, are crucial regulators of the B lymphocyte 
lineage, influencing both commitment to the B lymphocyte lineage and the progression of the 
immature B cells through the early stages of B lymphopoiesis. The importance of osteoblast 
lineage cells in B lymphopoiesis has been made apparent by their ability to support all stages of 
differentiation from HSCs to immature B cells in vitro, and the impaired formation of B 
lymphocyte precursors when osteoblasts are depleted from the bone marrow in vivo. It is 
ŝŵƉŽƌƚĂŶƚƚŽŶŽƚĞƚŚĂƚƚŚĞƚĞƌŵ “osteoblast ? has been used to describe a range of mesenchymal 
cell types that give rise to the osteoblast lineage [60]. Furthermore, as discussed above, the use 
of different mesenchymal cell lineage Cre strains does not necessarily identify the exact nature 
of the mesenchymal cell type involved in a given phenotype due to the potential targeting of 
downstream mesenchymal lineage cells in the Cre-targeted strains. 
 
The production of macrophages, granulocytes, megakaryocytes and erythrocytes from HSCs can 
occur readily in vitro when permissive cytokines are provided, however, stromal cells are 
required as feeder layers for the optimal production of lymphoid cells in vitro. Whitlock et al. [61] 
were the first to demonstrate that B lymphocytes could be produced in cultures containing 
adherent bone marrow cells, these cultures are now commonly known as Whitlock-Witte 
cultures. A range of osteoblast lineage primary cells and cell lines such as S17 and OP9 cells have 
since been shown to support the production of B lymphocyte lineage cells in co-culture in vitro 
assays [62, 63]. The OP9 stromal cell line is a cell line that was derived from the newborn calvaria 
of op/op mice, which lack functional macrophage colony-stimulating factor-1 (M-CSF, also known 
as colony-stimulating factor-1, CSF-1)[63, 64]]. The OP9 cell line was originally developed to 
improve methods for the differentiation of embryonic stem cells into erythroid, myeloid and B 
lymphoid lineages in vitro [63]. The OP9 cell line (and a variant that overexpresses delta-like 1, 
OP9-DL1 [65]) have since become routinely used cell lines for in vitro assays of B and T 
lymphopoiesis, respectively, from ES cells, adult HSCs and more committed hematopoietic 
progenitor cells. While the exact nature of the OP9 cell line is unclear, it can readily give rise to 
adipocytes [66], chondrocytes [67] and osteoblasts [68] when cultured with the appropriate 
differentiation-inducing media. Furthermore, the immunophenotype of OP9 cells [68] is similar 
to that of the population derived from bone marrow that expresses PDGFRɲĂŶd Sca-1 (PɲS) cells 
and gives rise to osteoblasts, adipocytes and chondrocytes in culture [69]. While these cells are 
often described as mesenchymal stem cells, their potential to form other mesenchymal lineages 
has not been shown, hence they are best termed skeletal stem cells [60].  
 
Furthermore, co-cultures of primary calvaria-derived osteoblasts or the stromal cell line S17 with 
HSCs supported the formation of B220+CD19+ B lymphocyte precursors [62]. Zhu et al. [62], 
isolated HSCs (GFP-Lin-Sca-1+c-Kit+; LKS+) from the bone marrow of RAG2 GFP NG BAC (B6) mice 
(which express GFP in committed early B lymphocyte precursors). When these LKS+ cells were co-
cultured with the primary osteoblast lineage cells, 15% of the progeny of the LKS+ cells became 
GFP+, indicating lymphocyte commitment. In comparison, no GFP+ cells were produced when LKS+ 
cells were co-cultured with the MS-1 endothelial cell line [62]. Stimulation of the osteoblast 
lineage cells with PTH for 3 days led to elevated levels of IL-7 and SDF-1 (CXCL12) expressed by 
the osteoblast lineage cells. Inhibition of IL-7, SDF-1 or thymic stromal cell-derived lymphopoietin 
(TSLP) during PTH stimulation reduced the number of B220+ B lymphocytes. Furthermore, 
inhibition of integrin Ƚ4 or VCAM-1 prevented the formation of B220+ cells. This indicates that 
osteoblast lineage cells support B lymphopoiesis through the secretion of IL-7, SCF-1 and TSLP 
and that VCAM-1/integrin Ƚ4 signalling is also important for osteoblastic-induction of B 
lymphopoiesis [62]. The calvarial-derived cells were shown to express Sca-1, CD61, ICAM-1 and 
VCAM-1 but lacked expression of endothelial and hematopoietic cell markers. These cells also 
expressed osteopontin in culture [62].  The expression of Sca-1 by these cells suggests that they 
are also akin to skeletal stem cells [23, 39, 69]. Hence, while these calvarial-derived cells are 
clearly of mesenchymal origin, the stage of osteoblast lineage maturation of the cells used in the 
cultures remains unclear. 
 
Zhu et al., found that ablation of Col1a1-2.3kb (Col2.3)-targeted osteoblasts in vivo using a 
thymidine kinase suicide gene in vivo depleted early B lymphocytes in the bone marrow [62]. 
When Col2.3-thymidine kinase mice were treated with ganciclovir, the thymidine kinase 
converted ganciclovir to an inhibitor of DNA polymerase, ganciclovir triphosphate, which is toxic 
to cells, killing those downstream of Col2.3. At 8 days after ganciclovir administration, 
osteocalcin-positive osteoblasts were shown to be depleted. This was accompanied by dramatic 
reductions in pre-pro-B (64%) and pro-B lymphocytes (81%) with modest reductions in pre-B and 
immature B lymphocytes [62]. In contrast, the numbers of LKS+ cells (containing a mix of HSCs 
and multipotent progenitor cells) were unaltered at this time point (Table 2). The numbers of B 
lymphocyte precursors continued to decline 28 days after ganciclovir treatment, at which point 
LKS+ cells were reduced and the hematopoietic cellularity in the bone marrow was dysregulated 
[62, 70]. This indicates that osteoblasts directly regulate early B lymphopoiesis in the bone 
marrow, and that this occurs prior to the loss of HSCs.  
 
A similar study ablated osteoblast-lineage cells using an inducible diphtheria toxin receptor to 
induce cell death in Osx1-GFP::Cre-targeted cells following administration of diphtheria toxin 
[71]. This resulted in a reduction in pre-B lymphocytes and mature B lymphocytes in the bone 
marrow and accumulation of pro-B cells and large pre-B cells, with no change to more primitive 
B lymphoid-lineage cells. The pre-B lymphocyte defect could be rescued with administration of 
insulin-like growth factor 1 (IGF-1), whereas IL-7 administration increased Pro-B cell but had no 
effect on Pre-B cells, implicating IGF-1 in regulation of pre-B cells [71]. 
 
A range of different targeted knockout mice using mesenchymal lineage cell specific-Cre models 
have also been described to have defects in B lymphopoiesis, which are further described below. 
 
4.1. Osteoclasts ʹ direct or indirect regulators? 
B lymphopoiesis can also be regulated by the activity of osteoclasts. Administration of the anti-
resorptive agent, zoledronic acid, led to reduced production of CXCL12 and IL-7 from stromal cells 
and a reduction in early B lymphocyte precursors from the pro-B lymphocyte stage in mice [72]. 
The reduction in B lymphocytes was a consequence of reduced production of CXCL12 and IL-7 
from the mesenchymal cells. Zoledronic acid did not have a direct effect on B lymphopoiesis or 
alter stromal cell production of Cxcl12 or Il7 in vitro [72]. This implicates osteoclast activation can 
indirectly regulate B lymphopoiesis through altering bone formation from osteoblast lineage 
cells. Interestingly, B lymphocytes can inhibit osteoclastogenesis (and, in turn, influence the 
regulation of osteoblasts) by secreting osteoprotegerin (OPG) [73]. Indeed, B cells at different 
stages of development, in particular mature B lymphocytes and plasma cells, have been shown 
to be the major source of OPG in mouse BM [73]. In inflammatory conditions, B lymphocyte 
populations can also secrete RANKL [74]. 
 
5. Extrinsic factors regulating B lymphopoiesis 
Chemokines, adhesion molecules and various cytokines expressed by stromal cells in the 
microenvironment are essential for the regulation of early B lymphopoiesis as either positive or 
negative regulators. These factors are known to govern specific stages of B lymphocyte 
development and must be delivered to the appropriate B cell precursor at the appropriate stage 
of development to enable healthy B cell maturation. While it is recognised that these factors are 
essential for the development of B lymphocytes, how B lymphocyte niches are integrated still 
requires further investigation. For example, the distinct stages of B lymphopoiesis are known to 
involve different cell types [55], however the exact nature of each of the cell types, and whether 
or not each B lymphocyte niche consists of one or more microenvironment cell type currently 
remains unclear. Furthermore, the different functional roles of individual cell types within these 
niches have not been fully characterised. We describe below known B lymphopoiesis regulatory 
factors that have been shown to be expressed by mesenchymal lineage cells. 
5.1. Directly-acting, positive extrinsic factors 
5.1.1.  CXCL12 
CXCL12 (also known as stromal cell-derived factor 1 or SDF1) is a chemokine produced by 
numerous microenvironment cells that is a key regulator of hematopoiesis. CXCL12 signals 
through its receptor, CXC-chemokine receptor 4 (CXCR4), which is expressed by a range of 
developing hematopoietic cell lineages [75]. CXCL12 is essential for regulating early B 
lymphopoiesis, at least in part by guiding the different B lymphoid progenitors to their correct 
niches [76],  and also regulates quiescence and the maintenance of HSCs in the bone marrow 
[23]. In addition, CXCL12 is  a key component involved in the homing of end stage B plasma cells 
to the bone marrow [23]. Early studies of SDF-/- (CXCL12-/-) mice found that CXCL12 expression 
was essential for the development of pre-pro-B lymphocytes [77]. B lymphocytes express CXCR4 
throughout differentiation, although the level of expression fluctuates and this affects the 
chemotactic effect of CXCL12 [78]. This means CXCL12-stimulated chemoattraction is strong in 
early B lymphopoiesis, is weakened in mature B lymphocytes as CXCR4 expression is suppressed 
and is then re-acquired by bone marrow-homing plasma cells [79]. The variation in CXCR4 
expression is due to coupling of different signalling cascades following CXCR4 activation during B 
lymphopoiesis [79]. 
 
The importance of microenvironment-produced CXCL12 in the initiation of B lymphopoiesis was 
recently demonstrated by Cordeiro Gomes et al. [76]. Deletion of the receptor for CXCL12, Cxcr4 
in Flk2Cre-targeted multipotent progenitor cells (MPPs) resulted in striking reductions in all blood 
cell lineages downstream of the MPPs. The impact on B lymphopoiesis was the most profound, 
with striking reductions in the early B lineage-committed Ly6D+ CLPs and all maturing B 
lymphocyte populations. Similar reductions in B lymphopoiesis were observed when Cxcr4 was 
deleted in Il7ra-expressing CLPs. Intriguingly, however, when the Cxcr4-deficient CLPs were 
cultured on OP-9 stromal cell layers (which express CXCL12) and the culture media was 
supplemented with IL-7, the Cxcr4-deficient CLPs differentiated into B cells as efficiently as the 
wildtype CLPs [76]. Elegant imaging studies showed that loss of Cxcr4 in the MPPs resulted in 
defective CLP localization to IL-7-expressing microenvironment cells [76]. 
 
B lymphocyte phenotypes reported in different mesenchymal-specific Cxcl12 knockout mice 
The role of CXCL12 in the microenvironment has recently been studied extensively by a number 
of investigations that involved deleting Cxcl12 in different cell types using transgenic Cre-
recombinase (Cre) mouse strains (Table 2). Deletion of Cxcl12 in Prrx1-targeted limb bud-derived 
mesenchymal stromal cells led to a substantial reduction in pre-pro-B lymphocytes, CLPs and 
HSCs, with an almost complete lack of quiescent HSCs and a loss of HSC repopulating activity [23]. 
When Cxcl12 was deleted in Osx-targeted osteoprogenitors HSC function was normal, however 
the mice exhibited constitutive HSC mobilisation and reduced numbers of B lymphoid progenitors 
[23] ?Žů ?ɲ ?-2.3kb (Col2.3)-Cre deletion of Cxcl12 had no effect on B lymphocytes but the mice 
exhibited reduced numbers of CLPs [26]. In comparison, deletion in Tie2-targeted endothelial 
cells and LepR-targeted stromal cell had no effects on B lymphopoieisis [26]. Interestingly, 
however, reduced HSC numbers [26] and repopulating activity [23] was observed when Cxcl12 
was deleted in endothelial cells and HSC mobilisation occurred when Cxcl12 was deleted in LepR-
targeted cells [26]. Deletion of Cxcl12 in Nestin-targeted perivascular cells [26] and in Osteocalcin-
targeted mineralising osteoblasts [23] did not alter HSCs or B lymphopoiesis. Thus expression of 
Cxcl12 in cells expressing Prrx1 or Osx and their progeny have important regulatory functions in 
B lymphopoiesis through the action of CXCL12. 
 
These studies support the theory for the existence of distinct niches regulating hematopoiesis in 
different ways. Osx-targeted cells provide a supportive niche for B lymphoid progenitors and also 
maintain HSCs in the bone marrow. In contrast, CXCL12 produced from perivascular 
mesenchymal cells and endothelial cells appear to be more important in the regulation of HSC 
number and function.  
 
It is important to consider that in these models, CXCL12 is not only deleted from the cell in which 
the Cre is expressed but also all of their progeny. Thus deleting Cxcl12 from Prrx1 mesenchymal 
stromal cells will also delete in all cells derived from Prrx1-expressing cells including osteoblastic, 
adipogenic, chondrogenic lineages and other stromal populations that are derived from limb bud 
mesenchymal stem cells. Thus deletion of Cxcl12 using Prrx1-Cre will delete Cxcl12 from more 
microenvironmental cell types compared to when deletion is restricted to cells in the late stages 
of differentiation, e.g. Osteocalcin-Cre. Thus the presence of more profound phenotypes when 
deleted in more primitive cells, such as Prrx1-targeted cells, could be due to the lack of CXCL12 
in larger numbers of microenvironmental cell types rather than the phenotype that would occur 
if the loss of CXCL12 was restricted only to cells that express Prrx1. Furthermore, there are often 
direct and indirect consequences of deletion of genes in a given cell type, hence this may also 
indirectly influence B lymphopoiesis in any of these mice. 
 
Table 2. Conditional models targeting cells in the bone marrow microenvironment and the 
effects on the B lymphocyte lineage 
Genetic model HSCs Progenitors B220+ Pre-pro-B Pro-B Pre-B Ref 
Cxcl12 
Prrx1-Cre+:Cxcl12 ȴ/- 
Ð HSCs (almost 
complete lack of 
quiescent HSCs) 
Ð repopulating 
activity 
Ð MPPs, 
CLPs, BLPs, 
CMPs 
Ð Ð Ð Ð [23, 
26] 
Nestin-Cre+:Cxcl12ȴͬȴ normal*^ normal  normal normal normal [26] 
LepR-Cre+:Cxcl12ȴͬȴ Ï mobilization normal  normal normal normal [26] 
Osx1-GFP::Cre+:Cxcl12 ȴ/- 
Normal HSC 
function, 
constitutive 
mobilization 
normal Ð Ð ND ND [23] 
Col1a1(2.3kb) -Cre+:Cxcl12 ȴͬȴ normal*^# 
Ð CLPs & 
LMPPs 
 normal normal normal [26] 
Osteocalcin-Cre+:Cxcl12ȴͬ- normal*^ normal normal normal ND ND [23] 
Tie2-Cre+:Cxcl12ȴͬȴ 
Ð HSCs, Ð long-
term repopulating 
activity 
normal  normal normal normal 
[23, 
26] 
Il7 
Prrx1-Cre+:Il7ȴͬ- normal* normal ND ND Ð Ð [76] 
LepR-Cre+:Il7ȴͬ- normal* 
Ð Ly6D+ 
CLPs 
ND ND Ð Ð [76] 
Col1a1(2.3kb) -Cre+:Il7 ȴͬ- normal* normal ND ND normal normal [76] 
Tie2-Cre+:Il7 ȴͬ-  normal ND ND Ð Ð [76] 
Scf (Kitl) 
Il7-Cre:Scf ȴͬȴ Ð Ð MPPs ND ND normal normal [76] 
Nestin-Cre+:Scfȴͬ- normal*^ ND normal ND ND ND [27] 
Nestin-CreER+:Scfȴͬȴ + 
tamoxifen 
normal*^ ND ND ND ND ND [27] 
LepR-Cre+:Scfȴͬ- Ð HSCs ND ND ND ND ND [27] 
Col1a1(2.3kb) -Cre+:Scf ȴͬ- normal*^ ND normal ND ND ND [27] 
Tie2-Cre+:Cxcl12ȴͬ- 
Ð HSCs, Ð long-
term repopulating 
activity 
ND ND ND ND ND [27] 
'Ɛɲ 
Osx1-GFP::Cre+:Gsɲȴͬȴ ND ND Ð normal Ð Ð [56] 
Dmp1-Cre+:Gsɲȴͬȴ normal* normal normal ND ND ND [80] 
Pth1r 
Col1a1(2.3kb) -Cre+:Pth1r tg/tg 
(constitutively active) 
ÏHSCs ND ND ND ND ND [28] 
Rarg 
Nestin-Cre+:Rargȴͬȴ normal*^ normal Ð normal normal Ð [25] 
Osx1-GFP::Cre+:Rargȴͬȴ normal*^ normal normal normal normal normal [25] 
IGF-1 
Osx1-GFP::Cre:Igf1ȴͬȴ ND ND  normal Ï Ð [71] 
Osteoblast ablation 
Osx1-GFP::Cre:iDTR + 
diphtheria toxin 
normal*^ Ï GMP  normal Ï~ Ð  [71] 
Col1a1(2.3kb)-Cre+: ȴTK + 
ganciclovir 
Ð day 21 ND Ð 
day 8 
Ð 
day 8 
Ð 
day 8 
Ð 
day 8 
[62] 
Recombined floxed allele (ȴ), null allele (-), transgenic allele (tg). Significant changes compared to appropriate 
controls are identified by: elevated function or numbers (Ï), lower function or numbers (Ð), normal or not 
determined (ND). Haematopoietic stem cell (HSC), multipotent progenitor (MPP), B lymphoid-biased progenitors 
(BLPs), common lymphoid progenitor (CLP), lymphoid-primed multipotent progenitor (LMPP), inducible diptheria 
toxin receptor (iDTR) and thymidine kinase (TK). *Normal HSC frequency, ^normal repopulating activity. #Data were 
based on FACS-isolated HSC transplants, however transplants using whole bone marrow cells showed significantly 
impaired lymphoid repopulation. ~&ƌĂĐƚŝŽŶǁĂƐŶŽƌŵĂůĂŶĚ&ƌĂĐƚŝŽŶ ?ĂŶĚ ? ?ǁĞƌĞŝŶĐƌĞĂƐĞĚ ? 
 
 
5.1.2.  IL-7 
IL-7 is also known to play an essential role in B lymphopoiesis. IL-7 signals through the IL-7 
receptor (IL-7R), which is expressed by B lymphocyte precursor populations until the large pre-B 
cell stage with subsequent B cell populations lacking expression of the IL-7R [81, 82]. Deletion of 
either IL-7 or IL-7R led to reductions in pro-B and pre-B lymphocytes with no change to pre-pro-
B lymphocytes [82, 83]. This suggests the role of IL-7 in B lymphopoiesis occurs subsequent to 
CXCL12, from the pro-B cell stage onwards.  
 
IL-7 has been shown to induce the proliferation of pro-B cells, but not pre-pro-B cells, in vitro 
(85). In accordance with this, Il7 deficient mice demonstrated a marked loss in the numbers of 
pro-B cells and pre-B cells and their later differentiated stages (86, 87). While no changes in pre-
pro B cells were observed in Il7 knockout mice, their differentiation was severely impaired, which 
may have resulted in the reductions of the more mature populations (86).  
 
The mechanism of action of IL-7 includes the induction of the expression of myeloid-cell leukemia 
sequence 1 (MCL1) in the developing B cell precursors to mediate their survival (88). 
Furthermore, it has been reported that overexpression of early B cell factor (EBF) can counteract 
the Il7-deficient B cell phenotypes (89). 
 
Elegant lineage tracing studies where Il7-Cre transgenic mice were crossed to Rosa26EYFP mice 
demonstrated that the IL-7-expressing cells in the bone marrow were predominantly bipotent 
CAR cells that expressed LepR and could give rise to both adipocytes and osteoblasts in vivo [76]. 
Deletion of Cxcl12 in Il7-Cre-targeted cells resulted in a significant loss in HSCs, CLPs, and 
developing B cells in the bone marrow. Interestingly, the numbers of these cells were normal in 
the spleen, hence increased mobilization to the spleen was an unlikely cause of the reduced bone 
marrow cells [76].  
 
IL-7-dependent B lymphocyte phenotypes that have been reported in different mesenchymal 
cell-specific knockout mice. 
IL-7 production by osteoblastic cells has been shown to be important for B lymphopoiesis via the 
regulatory actions of 'Ɛɲ, a downstream mediator of PTHR1 signalling. Deletion of 'ƐɲŝŶOsx-
Cre-targeted osteoblast progenitors leads to severe osteoporosis and reduced B lymphocyte 
precursors in the bone marrow [56, 84]. Osx-'&W͗͗ƌĞ'Ɛɲfl/fl (GsaOsxKO) mice exhibited 
significantly reduced proportions of pro-B and pre-B lymphocytes, with no change to pre-pro-B 
lymphocytes in their bone marrow [56] ? dŚĞ 'Ɛɲ-deficient osteoblast lineage cells expressed 
significantly reduced levels of IL-7. Administration of IL-7 into GsaOsxKO mice or transplant of 
GsaOsxKO bone marrow into wild type mice was able to rescue the B lymphocyte defects [56]. Thus 
IL-7 produced by Osx-targeted cells regulates pro-B and pre-B lymphopoiesis. 
 In their recent study, Cordeiro Gomes et al. [76] deleted Il7 in a range of mesenchymal cell types 
and determined the subsequent impact on B lymphopoiesis. Deletion of Il7 in Lepr-Cre-targeted 
cells resulted in a significant reduction in BLPs in the mice. This was accompanied by significant 
reductions in all downstream B lymphocyte populations, including significantly reduced 
peripheral blood B lymphocytes. The numbers of pro-B, pre-B and B220+IgM+ B lymphocytes in 
the bone marrow were also significantly reduced in mice lacking Il7 in Prrx1Cre-targeted cells. In 
contrast, when Il7 was deleted in mature osteoblasts using Col2.3Cre, no hematopoietic 
phenotype was observed. Interestingly, when Il7 was deleted in Tie2-Cre-targeted cells (which 
deletes in endothelial and hematopoietic cells [17], there were small, but significant reductions 
in the numbers of pro-B and pre-B cells in the bone marrow.  
 
 
 
x I would include here Aguila, JBMR 2012 showing that osteoblast-specific expression of 
IL-7 can rescue the B cell and bone phenotype of IL-7 KO mice:  
o J Bone Miner Res. 2012 May;27(5):1030-42. doi: 10.1002/jbmr.1553. 
Osteoblast-specific overexpression of human interleukin-7 rescues the bone 
mass phenotype of interleukin-7-deficient female mice. 
Aguila HL1, Mun SH, Kalinowski J, Adams DJ, Lorenzo JA, Lee SK. 
 
 
 
 
 Figure 3: Identifiers of B lymphocyte subsets and extrinsic regulators of B lymphopoiesis 
Expression of cell surface antigens allows for identification of B lymphocyte subsets in the bone 
marrow. The purple panel indicates expression of B220, IgM, CD19, CD43, CD24 (HSA), BP-1 (6C3) 
and IgD through differentiation from pre-pro-B lymphocytes to immature B lymphocytes and in 
recirculating mature B lymphocytes plus the corresponding fraction [85]. Expression as 
determined by flow cytometry is indicated as positive (+), positive-bright (++) or negative (-). The 
green panel indicates positive (+) and negative (-) expression of receptors and adhesion 
molecules involved in stimulating or repressing B lymphopoiesis. The blue panel indicates 
extrinsic factors expressed by stromal cells in the microenvironment are important in the 
development of early B cell precursors and the specific stages they regulate (+) in the bone 
marrow and are discussed in this review.  
 
5.1.3.  FLT3L 
FMS-like tyrosine kinase 3 ligand (FLT3L) is a growth factor that binds to FLT3 (also known as 
CD135), which is expressed on the cell surface of lymphoid-primed multipotent progenitor cells, 
CLPs and pre-pro B lymphocytes. It is important for early B lymphocyte commitment [5], and acts 
synergistically with IL-7 to promote B lymphopoiesis [86, 87]. FLT3L has been shown to be 
produced by a range of hematopoietic cell types [88], but is also produced by bone marrow 
stromal cells.  The nature of the latter cell type(s) is unclear. 
 
Mice deficient in FLT3 or FLT3L exhibited reduced numbers of pre-pro-B and pro-B lymphocytes 
in their bone marrow [89, 90]. Furthermore, mice deficient in FLT3L also had a marked reduction 
in bone marrow pre-B lymphocytes [90]. FLT3 is expressed by pre-pro-B lymphocytes until their 
irreversible commitment to the B lymphocyte lineage, when it is repressed by the expression of 
Pax5 [91]. Thus FLT3L is an important regulator of the earliest stages of B lymphopoiesis.  
 
5.1.4.  SCF 
Stem cell factor (SCF, also known as KIT ligand; KITL) is a cytokine that signals though the c-kit 
receptor (also known as CD117), which is a receptor tyrosine kinase that is expressed on the cell 
surface of many developing hematopoietic cell types, including HSCs. SCF is primarily expressed 
by perivascular cells and exists as membrane-bound or secreted forms [5, 27, 81]. SCF synergizes 
with IL-7 in vitro to induce the proliferation of pro-B cells [92]. Furthermore, loss of Scf in Il7-Cre 
transgenic mice resulted in a significant reduction in HSCs and MPPs in the bone marrow of the 
mice [76].  
 
Neonatal mice deficient in c-kit (termed W/W) do not display any B lymphocyte defects, however 
W/W mice die within 1 week of birth due to anemia [93]. When the anemic phenotype was 
rescued by administration of erythropoietin, it was found that pro-B and pre-B lymphocyte 
numbers decreased with age in these mice [94]. This indicates that SCF is important for B 
lymphopoiesis in adults.  
 
A range of mice in which Scf was deleted in microenvironment-specific cell types have recently 
been reported [27] (Table 2). These studies focused on the HSC phenotypes of the mice, however, 
and to date only the B lymphopoiesis phenotypes have been reported for the mice in which Scf 
was deleted in Nestin-expressing or Col2.3-expressing cells. Both mouse strains had normal 
numbers of B220+ cells in their bone marrow  [27]. 
 
5.1.5.  IGF-1 
IGF-1 is expressed by Osx1-GFP::Cre-targeted cells that binds to the IGF-1 receptor (IGF-1R) on 
B lymphocytes to promote transition from the pro-B to the pre-B lympohocyte stage [71]. Igf1 
levels are reduced in the bones of Osx1-GFP::Cre:iDTR mice after administration of diphtheria 
toxin to ablate Osx1-Cre-targeted cells and mice exhibit defective B lymphopoiesis [71]. Mice 
with targeted deletion of IGF-1 using Osx1-GFP::Cre exhibit reduced numbers of pre-B, 
immature and mature B lymphocytes in the bone marrow, but increases in cells in fractions B, 
 ? ?ĂŶĚ ? ? identifying pro-B and earlier pre-B lymphocytes [71]. This implicates IGF-1 derived 
from Osx1-Cre-targeted cells as important in regulating the later stages of B lymphopoiesis 
within the bone marrow from fraction D small pre-BII cells. 
 
5.1.6.  Sclerostin 
For you to consider  ? one paper demonstrating a B cell defect in mice lacking sclerostin, a 
negative regulator of canonical Wnt signalling. Potentially clinically relevant since anti-sclerostin 
antibody is in development as an osteoporosis medication: 
J Bone Miner Res. 2012 Jul;27(7):1451-61. doi: 10.1002/jbmr.1608. Absence 
of sclerostin adversely affects B-cell survival. Cain CJ1, Rueda R, McLelland B, Collette 
NM, Loots GG, Manilay JO. 
 
Osteonectin 
x Luo et al 2014  ? SPARC deficiency affects bone marrow stromal cell function, resulting in 
impaired B lymphopoiesis.  https://www.ncbi.nlm.nih.gov/pubmed/24598056 Æ 
probably due to reduced osteoblasts 
 
5.1.7.  VCAM-1 
Adhesion 
x Tokoyoda  ? Cxcl12 increases VLA-4 VCAM-1 adhesiveness in pre-pro-B cells 
but not pro-B or pre-B cells 
x Park, S. Y. et al. Focal adhesion kinase regulates the localization and retention of pro-B 
cells in bone marrow microenvironments. J. Immunol. 190, 1094 ?1102 (2013).  
x Ryan et al 1999  ? Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate 
adhesion of human B cell precursors to cultured bone marrow adherent cells 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC295504/ 
 
 
5.1.8.  Galectin-1 
Galectin-1 binds to integrins (including ɲ4E1, ɲ5E7 and ɲ4E7) that are expressed on the cell surface 
of a range of cell types [95]. Developing B lymphocytes express ɲ4E1 (VLA-4), which also binds to 
other cell adhesion molecules including VCAM-1.  
 
Galectin-1 was shown to be expressed in mature osteoblasts in addition to cells located 
throughout the bone marrow [54]. The Galectin-1+ cells obtained from flushed bone marrow 
were shown to express CD54+ but did not express VCAM- ? ? W'&Zɲ ? W-1, Sca-1 or Nestin. 
Interestingly, most Galectin-1+ cells obtained from flushed bone marrow were CD31+, but did not 
express CD34 or Tie2, suggesting that they were a subset of endothelial cells.  In IL-7-GFP reporter 
mice, Galectin-1 was not co-expressed with GFP, indicating that IL-7-expressing cells are a 
separate cell type to Galectin-1-expressing cells [54].  
 
Galectin-1-deficient mice had normal numbers of the different B lymphocyte populations in vivo 
in the steady state. In contrast, however, the recovery of pre-B II cells was significantly delayed 
in Gal1-/- mice after treatment with hydroxyurea [95]. 
 
 
5.2. Indirect, positive extrinsic factors 
5.2.1.  RANKL 
Receptor activator of nuclear factor kappa-B ligand [RANKL; also known as osteoprotegrin ligand 
(OPGL), encoded by the Tnfsf11 gene] is a protein with important functions in osteoclastogenesis 
and B lymphopoiesis. RANKL signals through RANK on osteoclasts, and together with macrophage 
colony stimulating factor (M-CSF), stimulates the expression of osteoclastic transcription factors, 
including nuclear factors of activated T cells c1 (NFATc1), microphalmia associated transcription 
factor (MITF), PU.1 and activator protein 1 (AP-1) [96, 97]. This induces myeloid precursors to 
differentiate into mononucleated osteoclasts, which form multinucleated osteoclast by fusing 
and finally activate becoming polarised osteoclasts that resorb bone [96, 97]. 
 
RANKL is produced by a range of osteoblast lineage cell types [98], in addition to B lymphocytes 
[99]. Mice deficient in RANKL (opgl-/-) exhibited severe osteopetrosis and reduced numbers of B 
lymphocyte precursors [100]. Differentiation of splenic osteoclast precursor cells from opgl-/- and 
opgl+/+ mice revealed opgl-/- splenic cells displayed comparable osteoclastogenic capacity to 
opgl+/+ cells when cultured with exogenous RANKL and M-CSF.  In comparison, co-cultures of 
either opgl+/- or opgl-/- osteoblasts with wild type non-adherent bone marrow cells found opgl+/- 
osteoblasts, but not opgl-/- osteoblasts, could support osteoclastogenesis. This means the 
osteopetrotic phenotype in opgl-/- mice is due to impaired osteoclastogenesis caused by a lack of 
RANKL production from osteoblasts rather than an intrinsic loss in osteoclast progenitors.  
 
When immunodeficient recombination-activating gene 1 null (Rag1ʹ/ʹ) mice (which lack mature 
B and T cells) were reconstituted with opgl-/- foetal liver cells (the predominant site of 
hematopoiesis in embryos), there was a reduction in pre-B lymphocyte and immature B 
lymphocytes in the recipients compared to mice transplanted with opgl+/+ bone marrow [100]. 
Interestingly, when opgl-/- mice were transplanted with wild type bone marrow, the mice 
exhibited normal B cell development. This suggests that loss of RANKL in non-hematopoietic 
microenvironment cells was not sufficient to cause the defects in B lymphopoiesis.  
 
Similarly, when Rank was deleted in mice, severe osteopetrosis was accompanied by significantly 
reduced bone marrow hematopoiesis (<10% of normal) [101]. The spleens of Rank-/- mice were 
enlarged, with the spleen-to-body weight being twice the size of wildtype littermates. Despite 
this, there was a 50% reduction in B cells in the Rank-/- spleens, whereas all other hematopoietic 
cell lineages were normal (T cells, macrophages) or elevated (granulocytes, erythrocytes). Note, 
however, that mb1-Cre deletion of Rank in B lymphocytes from the pro-B cell stage onwards did 
not result in any defect in B lymphopoiesis in the conditional knockout mice, suggesting that any 
effect of perturbing RANKL/RANK signaling on B lymphopoiesis is indirect [102]. Given that both 
the opgl-/- and Rank-/- mice had significant osteopetrotic phenotypes, it is likely that the 
subsequent changes in the bone marrow microenvironment contributed to the B lymphocyte 
defects in these mice. 
 
x Discuss paper by Yun et al 2001  ? opg-/- mice see Horowitz review 
x https://www.ncbi.nlm.nih.gov/pubmed/20601290 
 
5.3. Negative extrinsic regulators 
OSF-5 
o Identification of osteoblast stimulating factor 5 as a negative regulator in the B-lymphopoietic 
niche (Fujita et al 2015 Experimental Haematology) 
https://www.ncbi.nlm.nih.gov/pubmed/26213229 
 
 
Each of these factors produced extrinsically to B lymphocytes is important for healthy B 
lymphocyte production. Yet how each niche is organised to regulate distinct functions and the 
specific cell types involved in each process requires further investigation. Further insights have 
been gained by understanding the influence on B lymphopoiesis of signalling pathways of 
importance for regulating bone. 
 
6. Signaling pathways involved in microenvironment regulation of B lymphopoiesis by 
mesenchymal cells 
6.1. PTH 
ŝƐĐƵƐƐWd,ŝŶKƐĂŶĚƚŚĞŶůŝŶŬƚŽ:ŽǇ ?ƐƉƵďůŝĐĂƚŝŽŶƐďƵƚĚŽŶ ?ƚďĞƌĞƉĞƚŝƚŝǀĞǁŝƚŚŽƚŚĞƌƐĞĐƚŝŽŶƐ 
 Further investigation into the role of PTH in osteoblasts has solidified its significance in regulation 
of B lymphopoiesis via IL-7. Osx-Cre-targeted deletion of PTH receptor 1 (PTHR1) [7] or the GS 
alpha subunit (GSɲ ?ĚŽǁŶƐƚƌĞam signalling mediator [56, 84] caused reductions in bone marrow 
pro-B and pre-B lymphocytes and development of severe osteoporosis. This B lymphocyte 
phenotype was rescued by administration of IL-7 or by transplanting GSɲ-deficient bone marrow 
into wild type mice [56].  
6.2. Estrogen  
x DĂŶŽůĂŐĂƐ ?^ ? ? ?K ?ƌŝĞŶ ? ? ? ?ĂŶĚAlmeida, M. (2013) The role of estrogen and androgen 
receptors in bone health and disease. Nat. Rev. Endocrinol. 9, 699 ?712 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971652/ 
 
x Smithson, G., Beamer, W. G., Shultz, K. L., Christianson, S. W., Shultz, L. D., and Kincade, P. W. 
(1994) Increased B lymphopoiesis in genetically sex steroid-deficient hypogonadal (hpg) mice. J. 
Exp. Med. 180, 717 ?720 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2191601/ 
 
 
x Masuzawa, T., Miyaura, C., Onoe, Y., Kusano, K., Ohta, H., Nozawa, S. and Suda, T. (1994) 
Estrogen deficiency stimulates B ymphopoiesis in mouse bone marrow. J Clin Invest. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC295170/ 
x Fujiwara - RANKL (Receptor Activator of NF_B Ligand) Produced by Osteocytes Is Required 
for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice 
x  
 
6.3. Retinoic acid receptors 
Retinoic acid receptors (RARs) are expressed by many cells in the bone marrow 
microenvironment, and regulate hematopoiesis (including B lymphopoiesis) [25, 103-106] and 
bone remodelling [107-111] through direct and indirect means. Canonical RAR signalling occurs 
ƚŚƌŽƵŐŚ ŶƵĐůĞĂƌ ZZƐ ŽĨ ǁŚŝĐŚ ƚŚĞƌĞ ĂƌĞ ƚŚƌĞĞ ƐƵďƚǇƉĞƐ ? ɲ ? ɴ ĂŶĚ ɶ[108]. RARs form 
heterodimers with retinoid X receptors (RXRs) and associate with retinoic acid response elements 
(RAREs) were they regulate gene transcription. The effect of retinoids on hematopoiesis depends 
on the cell types that are exposed and the RAR subtype targeted. 
 
The role of RARs in microenvironment regulation of hematopoiesis has been studied using global 
and conditional deletion of RARs in mice. Rara-/- mice do not exhibit defects in bone [109] or 
hematopoiesis [105, 112]. Rarb-/-  and Rarb2-/-  mice appear normal and have no reported skeletal 
abnormalities, although these have not been extensively investigated in adult mice, nor have the 
hematopoietic phenotypes of these mice been reported [113, 114]. In comparison, Rarg-/- mice 
have significantly reduced trabecular bone [109]. Furthermore,  Rarg-/- mice have significant 
reductions in pro-B and pre-B lymphocytes [25] and have reduced levels of Il7 mRNA in their bone 
marrow [109]. Rarg-/- mice also develop a myeloproliferative-like syndrome (MPS) exhibiting 
increased granulocyte/macrophage progenitors and granulocytes in bone marrow, peripheral 
blood, and spleen [106]. Transplant studies revealed the defect in B lymphopoiesis and the MPS-
like syndrome were due to extrinsic loss of RARɶĨƌŽŵŶŽŶ-hematopoietic cells. Transplantation 
of wild type bone marrow into Rarg-/- mice led to development of the hematopoietic defects, 
whereas these defects were resolved when Rarg-/- bone marrow was transplanted into wild type 
mice.  
 
The hematopoietic phenotypes have recently been assessed in mice with conditional deletion of 
Rarg-/- in nestin and osterix-targeted microenvironmental cells [25]. Deletion of Rarg-/- in osterix-
expressing osteoblast progenitor cells produced no hematopoietic phenotype and B 
lymphopoiesis was normal [25]. However, mice with deletion of Rarg in nestin-Cre-targeted cells 
had normal numbers of pro-B lymphocytes but significantly reduced numbers of bone marrow 
pre-B lymphocytes and immature B220+IgM+ B lymphocytes, in addition to significantly reduced 
numbers of peripheral blood B lymphocytes [25]. The effects on early B lymphocytes were not as 
profound in Nestin-Cre+:Rargȴͬȴ mice as those observed in Rarg-/- mice, suggesting that additional 
cell types in the bone marrow are likely involved in the regulation of B lymphopoiesis by RARɶ. 
7. B lymphocyte stimulation of osteoclastogenesis 
This review has focused on the importance of bone and osteoblast-lineage cells in supporting B 
lymphopoiesis, yet it is also interesting to note that B lymphocytes are capable of influencing 
bone mass via stimulation of osteoclastogenesis. Studies in ovariectomized mice revealed that, 
along with osteoclast-driven bone loss, the mice exhibited an increase in B lymphopoiesis and an 
accumulation of B220+ cells in the bone marrow [115]. Similarly, mice treated with IL-7 to 
stimulate B lymphopoiesis also had enhanced osteoclastogenesis and less bone than controls and 
Il7-/- mice had higher trabecular bone volume [115]. Numerous cytokines that are normally 
suppressed by estrogen are known to contribute to ovariectomy-induced osteoclastogenesis, yet 
the increase in B lymphocytes drew light to the idea that B lymphocytes may be positive 
regulators of osteoclast formation.  
 
B lymphocytes express RANKL [99] and deletion of RANKL from B lymphocytes using CD19-Cre 
protected against ovariectomy-induced trabecular bone loss by impairing osteoclastogenesis [3]. 
In contrast, non-ovariectomised CD19-Cre+:Tnfsf11ȴͬȴ mice did not exhibit any bone loss during 
the 7 month period of analysis [3]. Ovariectomy did not increase Tnfsf11 expression by B 
lymphocytes, but increased the numbers of RANKL-expressing B lymphocytes and sRANKL levels 
in the bone marrow, implying a net increase in RANKL due to increased B lymphocyte numbers 
[3]. In B lymphocytes the RANKL/OPG axis is regulated by mechanistic target of rapamycin 
complex 1 (mTORC1) [116]. Deletion of a negative regulator of mTORC1, tuberous sclerosis 
complex 1 (TSC1), in B lymphocytes using CD19-Cre increased RANKL expression and 
downregulated OPG in B cells. As a result, CD19-Cre+:Tsc1ȴͬȴ mice had reduced trabecular bone 
mass and increased numbers of osteoclasts ǀŝĂ ƌĞŐƵůĂƚŝŽŶ ŽĨ ɴ-catenin [116]. Under normal 
conditions the contribution of B lymphocyte-derived RANKL is not integral for maintaining normal 
bone mass, likely due to contributions of many other cell types in the bone marrow 
microenvironment. However, a clear role has been established for RANKL produced by B 
lymphocytes during estrogen deficiency, suggesting that B cells are capable of contributing to 
osteoclast-driven bone loss. This emphasises the potential of B lymphocytes to regulate 
osteoclastogenesis, meaning that perturbed function of cells in the B cell lineage can have serious 
consequences for bone health. Additional examples of mice in which there are reciprocal 
relationships between B lymphocytes, osteoclasts and bone mass include Cntf-/- mice [117] and 
others that were recently reviewed by Manilay and Zouali [6]. 
 
8. Osteoblasts and multiple myeloma  
Multiple myeloma is a malignancy of plasma cells in the bone marrow in which the tumour cells 
act on cells in the bone marrow microenvironment to create a favourable niche for tumour 
growth. Myeloma causes a destructive bone disease in up to 90% of patients [118] resulting in 
bone pain, hypercalcemia and pathological fractures severely reducing quality of life [119], and 
increasing the risk of death by 20% [120]. The bone disease develops due to an uncoupling of 
bone remodelling. Factors that stimulate formation and activity of osteoclasts sare secreted 
directly from myeloma cells and indirectly from osteoblasts following myeloma cell adhesion (e.g. 
RANKL, IL-6, IL-1ɴ, IL-3, macrophage inhibitory protein 1ɲ; MIP- ?ɲ ?tumouƌ ŶĞĐƌŽƐŝƐ ĨĂĐƚŽƌɲ ?
dE&ɲ ? ?dŚŝƐ results in enhanced resorption, formation of osteolytic lesions and loss of trabecular 
bone structure [121]. The bone disease is exacerbated by concurrent release of osteoblast 
inhibitory factors (e.g. dickkopf-1; DKK1, secreted frizzled-related protein 2 (SFRP2) and SFRP3) 
which block differentiation of osteoblasts and thus impair formation of new bone [122-124]. As 
bone is resorbed additional factors that further promote osteoclastogenesis are released from 
the bone matrix such as transforming growth factor receptor ɴ (TGFɴ) which stimulates 
osteoclast formation and inhibits any osteoblast differentiation [125-127]. In osteoblasts and BM 
stromal cells TGFɴ increases secretion of factors that stimulate MM growth (e.g. IL-6, insulin-like 
growth factor 1; IGF-1) [121, 125] ?ƉƌŽŵŽƚŝŶŐƚƵŵŽƵƌŐƌŽǁƚŚĂŶĚĞƐƚĂďůŝƐŚŝŶŐƚŚĞ ‘ǀŝĐŝŽƵƐĐǇĐůĞ ?
of myeloma progression and bone destruction.  
 
More recently it has also been established that osteoblast-lineage cells and osteoclasts control 
myeloma cell dormancy [20] implicating bone cells in chemotherapy evasion and relapse. 
Myeloma cell engagement with bone lining cells or osteoblasts induces a dormant state where 
cells are resistant to chemotherapeutics that target proliferating cells [20]. These dormant cells 
remain in patients with minimal residual disease. The dormant state can be reversed by resorbing 
osteoclasts which reactivate dormant myeloma cells facilitating tumour expansion [20]. 
Chemotherapy resistance in myeloma is also conferred through myeloma adhesion to stromal 
cells via VCAM-1:VLA-4 binding and expression of microRNA-15a [128, 129]. While the role of 
osteoblasts and osteoclasts in myeloma dormancy is still under investigation, this clearly 
demonstrates the processes of bone remodelling and myeloma growth are intricately 
intertwined. 
9. Conclusions 
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